ResearcherFred Hutch Cancer CenterActive in the last 2 years

Christopher I. Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1543-0743; OpenAlex author ID A5047073464. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2026: 1 paper

Papers 1

Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer. Co-author DOI 10.1038/s43018-026-01158-7 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Duxin Sun · 1 shared paper, 2026 · strength 0.22
- Paper Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic… DOI 10.1038/s43018-026-01158-7 ↗
Lawrence H. Fong · 1 shared paper, 2026 · strength 0.22
- Paper Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic… DOI 10.1038/s43018-026-01158-7 ↗
Vaibhav Sahai · 1 shared paper, 2026 · strength 0.22
- Paper Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic… DOI 10.1038/s43018-026-01158-7 ↗
Deepak Nagrath · 1 shared paper, 2026 · strength 0.22
- Paper Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic… DOI 10.1038/s43018-026-01158-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.